Iterum Therapeutics PLC

Company Profile

Iterum Therapeutics PLC had its IPO on 2018-05-25 under the ticker symbol ITRM.

The company operates in the Healthcare sector and Biotechnology industry. Iterum Therapeutics PLC has a staff strength of 14 employees.

Stock update

Shares of Iterum Therapeutics PLC opened at $0.75 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.75 - $0.8, and closed at $0.79.

This is a +2.04% increase from the previous day's closing price.

A total volume of 12,017 shares were traded at the close of the day’s session.

In the last one week, shares of Iterum Therapeutics PLC have slipped by -11.37%.

Iterum Therapeutics PLC's Key Ratios

Iterum Therapeutics PLC has a market cap of $11.35 million, indicating a price to book ratio of 0.4454 and a price to sales ratio of 1349.785.

In the last 12-months Iterum Therapeutics PLC’s revenue was $0 with a gross profit of $37000 and an EBITDA of $-32551000. The EBITDA ratio measures Iterum Therapeutics PLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Iterum Therapeutics PLC’s operating margin was 0% while its return on assets stood at -33.58% with a return of equity of -220.84%.

In Q2, Iterum Therapeutics PLC’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

Iterum Therapeutics PLC’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-4.65 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Iterum Therapeutics PLC’s profitability.

Iterum Therapeutics PLC stock is trading at a EV to sales ratio of 105.2207 and a EV to EBITDA ratio of 0.5337. Its price to sales ratio in the trailing 12-months stood at 1349.785.

Iterum Therapeutics PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$51.02 million

Total Liabilities

$10.83 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Iterum Therapeutics PLC ended 2024 with $51.02 million in total assets and $0 in total liabilities. Its intangible assets were valued at $51.02 million while shareholder equity stood at $7.13 million.

Iterum Therapeutics PLC ended 2024 with $0 in deferred long-term liabilities, $10.83 million in other current liabilities, 130000.00 in common stock, $-445059000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $13.73 million and cash and short-term investments were $44.73 million. The company’s total short-term debt was $0 while long-term debt stood at $31.92 million.

Iterum Therapeutics PLC’s total current assets stands at $47.65 million while long-term investments were $0 and short-term investments were $31.00 million. Its net receivables were $127000.00 compared to accounts payable of $3.72 million and inventory worth $-127000.00.

In 2024, Iterum Therapeutics PLC's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Iterum Therapeutics PLC paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.79

52-Week High

$2.1499

52-Week Low

$0.601

Analyst Target Price

$1

Iterum Therapeutics PLC stock is currently trading at $0.79 per share. It touched a 52-week high of $2.1499 and a 52-week low of $2.1499. Analysts tracking the stock have a 12-month average target price of $1.

Its 50-day moving average was $1.01 and 200-day moving average was $1.1 The short ratio stood at 1.36 indicating a short percent outstanding of 0%.

Around 124.6% of the company’s stock are held by insiders while 128.5% are held by institutions.